What are the advantages of percutaneous transcatheter treatment over systemic therapy for deep venous thrombosis (DVT)?

Updated: Oct 30, 2020
  • Author: Donald Schreiber, MD, CM; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print
Answer

Answer

Direct intrathrombus injection of the thrombolytic agent protects the medication from deactivation by circulating inhibitors and achieves higher drug concentration at the site of thrombosis with a lower total dose than would be used for systemic intravenous thrombolytic therapy. The lower circulating drug levels are the suggested mechanism for the lower incidence of systemic and, in particular, intracranial hemorrhagic complications reported with catheter-directed thrombolysis.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!